Seroatlas · Human Serome Atlas

SIGLEC7

Sialic acid-binding Ig-like lectin 7

Also known as: CD328, p75/AIRM1, QA79, SIGL7_HUMAN, SIGLEC-7, SIGLEC19P, SIGLECP2

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q9Y286
Gene: SIGLEC7
Ensembl: ENSG00000168995
Chromosome: 19
Canonical length: 467 aa
Protein class: CD markers, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location: Vesicles,Plasma membrane
Secretome location: Intracellular and membrane

OverviewNCBI Gene

Predicted to enable sialic acid binding activity. Predicted to be involved in cell adhesion. Predicted to be located in membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

467 residues, UniProt reviewed canonical sequence.

>Q9Y286|SIGLEC7
     1  MLLLLLLPLL WGRERVEGQK SNRKDYSLTM QSSVTVQEGM CVHVRCSFSY PVDSQTDSDP
    61  VHGYWFRAGN DISWKAPVAT NNPAWAVQEE TRDRFHLLGD PQTKNCTLSI RDARMSDAGR
   121  YFFRMEKGNI KWNYKYDQLS VNVTALTHRP NILIPGTLES GCFQNLTCSV PWACEQGTPP
   181  MISWMGTSVS PLHPSTTRSS VLTLIPQPQH HGTSLTCQVT LPGAGVTTNR TIQLNVSYPP
   241  QNLTVTVFQG EGTASTALGN SSSLSVLEGQ SLRLVCAVDS NPPARLSWTW RSLTLYPSQP
   301  SNPLVLELQV HLGDEGEFTC RAQNSLGSQH VSLNLSLQQE YTGKMRPVSG VLLGAVGGAG
   361  ATALVFLSFC VIFIVVRSCR KKSARPAADV GDIGMKDANT IRGSASQGNL TESWADDNPR
   421  HHGLAAHSSG EEREIQYAPL SFHKGEPQDL SGQEATNNEY SEIKIPK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SIGLEC7 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.43
Highest tissue expression: 18 nTPM

Expression across tissuesHPA

Tissue

spleen: 18 nTPM
appendix: 10 nTPM
lymph node: 7.2 nTPM
liver: 6.9 nTPM
placenta: 5.8 nTPM
lung: 4.7 nTPM

Single-cell type

kupffer cells: 91 nCPM
monocytes: 30 nCPM
hofbauer cells: 27 nCPM
macrophages: 24 nCPM
nk-cells: 17 nCPM
innate lymphoid cells: 14 nCPM

Immune cell

eosinophil: 243 nTPM
classical monocyte: 140 nTPM
neutrophil: 117 nTPM
intermediate monocyte: 106 nTPM
NK-cell: 97 nTPM
total PBMC: 81 nTPM

Brain region

white matter: 3.7 nTPM
thalamus: 3.6 nTPM
medulla oblongata: 3.2 nTPM
pons: 2.6 nTPM
cerebral cortex: 1.8 nTPM
spinal cord: 1.8 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.09
gnomAD pLI: 0
gnomAD missense Z: 0.86
DepMap mean gene effect: -0.13
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

cell adhesion

Molecular functions

Cellular components

plasma membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SIGLEC7 as an antibody target. Whether an autoantibody or antibody against SIGLEC7 could matter depends on whether native SIGLEC7 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SIGLEC7 is annotated at the cell surface, where native SIGLEC7 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label SIGLEC7 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...